Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03354117 · ClinicalTrials.gov registry record · Phase 1
On Demand Contraception: Ulipristal Acetate Plus a COX-2 Inhibitor at Peak Fertility
A Phase 1 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT03354117: Completed Phase 1 study, sponsored by Stanford University.
NCT03354117 is a Phase 1 study that has completed, run by Stanford University. The registered enrollment target is 12 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03354117, a Phase 1 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
This is an exploratory prospective study investigating if addition of a COX-2 inhibitor can increase efficacy of ulipristal in disrupting ovulation at peak fertility.
Interventions
- DRUG Ulipristal Acetate 30 MG Oral Tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2018-03-15 |
| Est. Completion | 2019-05-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03354117
The ClinicalTrials.gov registry entry for NCT03354117 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ulipristal Acetate 30 MG Oral Tablet is the first listed.
NCT03354117 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03354117 about?
NCT03354117 is a clinical study titled "On Demand Contraception: Ulipristal Acetate Plus a COX-2 Inhibitor at Peak Fertility". This is an exploratory prospective study investigating if addition of a COX-2 inhibitor can increase efficacy of ulipristal in disrupting ovulation at peak fertility.
What is the current status of trial NCT03354117?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2018-03-15. Estimated completion is 2019-05-31.
What interventions are being tested in trial NCT03354117?
The interventions under investigation include: Ulipristal Acetate 30 MG Oral Tablet (DRUG).
Who is sponsoring clinical trial NCT03354117?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.